Please try another search
Vivoryon Therapeutics NV is a Germany-based clinical-stage biopharmaceutical company with focus on the research and development of new therapeutic products for the treatment of Alzheimer’s disease (AD) and other diseases with high medical need like Cancer and Fibrosis. The Company is developing a directed pipeline of product candidates with the project being a therapeutic approach for the treatment of AD. Its operations focus on the discovery and development of therapeutic programs, whereas operational research and development work is mainly outsourced to respective professional contract research organizations (CROs) or academic collaboration partners. Vivoryon strives to generate future revenues from licensing its product candidates to biopharmaceutical companies after development steps have been achieved or by commercializing products.
Name | Age | Since | Title |
---|---|---|---|
Erich M. Platzer | 73 | 2007 | Independent Non-Executive Chairman |
Charlotte Lohmann | 54 | 2015 | Independent Non-Executive Director |
Samir Shah | 62 | 2022 | Independent Non-Executive Director |
Claudia Riedl | 53 | 2022 | Independent Non-Executive Director |
Frank T. Weber | 64 | 2023 | Chairman of the Management Board, CEO, Chief Medical Officer & Executive Director |
Michael Schaeffer | 55 | 2018 | Chief Business Officer, Member of the Management Board & Executive Director |
Anne Doering | 51 | 2023 | CSO & Investor Relations Officer, CFO, Member of the Management Board and Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review